NEW YORK, June 20, 2011 /PRNewswire/ -- Andrew Technologies, LLC the maker of a new, suction-assisted liposuction system has named Tom Albright as Chief Executive Officer and Board Member.
Mr. Albright joins Andrew Technologies with almost 3 decades of drug, biologic, device and aesthetic-related sales, marketing, and general management experience. He has held leadership positions at Allergan (the world's leading aesthetic medical company), Nobel Biocare (the world's leading aesthetic dental company) and most recently was the President and General Manager of the Topical Aesthetic division at Syneron (the world's leading energy-based aesthetic device company). Mr. Albright began his healthcare career at Parke-Davis, and was a marketing director on the launch team of Lipitor® (the world's best-selling pharmaceutical product) and other popular brands.
Among the most noted accomplishments in his 11 years in aesthetic healthcare, Mr. Albright's experience includes: global leadership of the landmark BOTOX® Cosmetic launch, commercial lead for the development of Latisse®, North American leadership of the NobelActive® launch, and Global leadership of the elure™ launch at Syneron.
Mr. Albright has a BS in Biology from The Citadel and an MBA in Marketing from Mercer University.
"Our adipose-selective technology provides benefits for physicians and patients seeking aesthetic body contouring. We are thrilled to have Tom's leadership at Andrew Technologies, his extensive expertise in commercializing innovative medical aesthetics solutions offers a significant competitive advantage to our company," said Dr. Mark Andrew, Chief Scientific Officer of Andrew Technologies.
Bill Doyle, Managing Partner of WFD Ventures, stated, "Andrew Technologies is poised to provide high quality aesthetic body contouring to both patients and surgeons; and we are excited about working with Tom to assist the Company in executing its growth plan."
About Andrew Technologies, LLC
Andrew Technologies is a venture capital funded medical device company that will be based in Orange County, CA and is focused on the future launch of an FDA-cleared, adipose-selective lipoplasty system. The selective tissue liquefaction concept of this new lipoplasty system is based on the patented AquaLase® surgical modality of the Infiniti™ Vision System (the world's leading cataract surgical system) sold by Alcon Inc. (ACL). Dr. Mark Andrew is the co-inventor of both applications.
About WFD Ventures
WFD Ventures is a New York based venture capital firm investing in medical device companies with exceptional potentials. In addition to capital, WFD provides product development, regulatory and commercialization guidance to its portfolio companies. For more information, visit www.wfdventures.com .
SOURCE Andrew Technologies